These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

649 related items for PubMed ID: 21301358

  • 21. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating.
    Kim HJ, Vazquez Roque MI, Camilleri M, Stephens D, Burton DD, Baxter K, Thomforde G, Zinsmeister AR.
    Neurogastroenterol Motil; 2005 Oct; 17(5):687-96. PubMed ID: 16185307
    [Abstract] [Full Text] [Related]

  • 22. Clinical trial on the efficacy of a new symbiotic formulation, Flortec, in patients with irritable bowel syndrome: a multicenter, randomized study.
    Andriulli A, Neri M, Loguercio C, Terreni N, Merla A, Cardarella MP, Federico A, Chilovi F, Milandri GL, De Bona M, Cavenati S, Gullini S, Abbiati R, Garbagna N, Cerutti R, Grossi E.
    J Clin Gastroenterol; 2008 Sep; 42 Suppl 3 Pt 2():S218-23. PubMed ID: 18685503
    [Abstract] [Full Text] [Related]

  • 23. Efficacy and safety of Saccharomyces boulardii in the 14-day triple anti-Helicobacter pylori therapy: a prospective randomized placebo-controlled double-blind study.
    Cindoruk M, Erkan G, Karakan T, Dursun A, Unal S.
    Helicobacter; 2007 Aug; 12(4):309-16. PubMed ID: 17669103
    [Abstract] [Full Text] [Related]

  • 24. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome.
    Clavé P, Acalovschi M, Triantafillidis JK, Uspensky YP, Kalayci C, Shee V, Tack J, OBIS Study Investigators.
    Aliment Pharmacol Ther; 2011 Aug; 34(4):432-42. PubMed ID: 21679214
    [Abstract] [Full Text] [Related]

  • 25. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome.
    Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR.
    Aliment Pharmacol Ther; 2009 Mar 01; 29(5):508-18. PubMed ID: 19053980
    [Abstract] [Full Text] [Related]

  • 26. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS.
    Hun L.
    Postgrad Med; 2009 Mar 01; 121(2):119-24. PubMed ID: 19332970
    [Abstract] [Full Text] [Related]

  • 27. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
    Yoon JS, Sohn W, Lee OY, Lee SP, Lee KN, Jun DW, Lee HL, Yoon BC, Choi HS, Chung WS, Seo JG.
    J Gastroenterol Hepatol; 2014 Jan 01; 29(1):52-9. PubMed ID: 23829297
    [Abstract] [Full Text] [Related]

  • 28. A preliminary study of melatonin in irritable bowel syndrome.
    Saha L, Malhotra S, Rana S, Bhasin D, Pandhi P.
    J Clin Gastroenterol; 2007 Jan 01; 41(1):29-32. PubMed ID: 17198061
    [Abstract] [Full Text] [Related]

  • 29. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.
    Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA.
    Am J Gastroenterol; 2005 Jan 01; 100(1):115-23. PubMed ID: 15654790
    [Abstract] [Full Text] [Related]

  • 30. Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial.
    Choi CH, Kwon JG, Kim SK, Myung SJ, Park KS, Sohn CI, Rhee PL, Lee KJ, Lee OY, Jung HK, Jee SR, Jeen YT, Choi MG, Choi SC, Huh KC, Park H.
    Neurogastroenterol Motil; 2015 May 01; 27(5):705-16. PubMed ID: 25809913
    [Abstract] [Full Text] [Related]

  • 31. Osteopathy improves the severity of irritable bowel syndrome: a pilot randomized sham-controlled study.
    Florance BM, Frin G, Dainese R, Nébot-Vivinus MH, Marine Barjoan E, Marjoux S, Laurens JP, Payrouse JL, Hébuterne X, Piche T.
    Eur J Gastroenterol Hepatol; 2012 Aug 01; 24(8):944-9. PubMed ID: 22546751
    [Abstract] [Full Text] [Related]

  • 32. A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.
    Krause R, Ameen V, Gordon SH, West M, Heath AT, Perschy T, Carter EG.
    Am J Gastroenterol; 2007 Aug 01; 102(8):1709-19. PubMed ID: 17509028
    [Abstract] [Full Text] [Related]

  • 33. A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome.
    Camilleri M, Kim DY, McKinzie S, Kim HJ, Thomforde GM, Burton DD, Low PA, Zinsmeister AR.
    Clin Gastroenterol Hepatol; 2003 Mar 01; 1(2):111-21. PubMed ID: 15017503
    [Abstract] [Full Text] [Related]

  • 34. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study.
    Paré P, Gray J, Lam S, Balshaw R, Khorasheh S, Barbeau M, Kelly S, McBurney CR.
    Clin Ther; 2006 Oct 01; 28(10):1726-35; discussion 1710-1. PubMed ID: 17157129
    [Abstract] [Full Text] [Related]

  • 35. Short-term stability of subtypes in the irritable bowel syndrome: prospective evaluation using the Rome III classification.
    Engsbro AL, Simren M, Bytzer P.
    Aliment Pharmacol Ther; 2012 Feb 01; 35(3):350-9. PubMed ID: 22176384
    [Abstract] [Full Text] [Related]

  • 36. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
    Rahimi R, Nikfar S, Abdollahi M.
    Clin Ther; 2008 May 01; 30(5):884-901. PubMed ID: 18555935
    [Abstract] [Full Text] [Related]

  • 37. Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: a randomized, placebo-controlled trial.
    Søndergaard B, Olsson J, Ohlson K, Svensson U, Bytzer P, Ekesbo R.
    Scand J Gastroenterol; 2011 Jun 01; 46(6):663-72. PubMed ID: 21443416
    [Abstract] [Full Text] [Related]

  • 38. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial.
    Johannesson E, Simrén M, Strid H, Bajor A, Sadik R.
    Am J Gastroenterol; 2011 May 01; 106(5):915-22. PubMed ID: 21206488
    [Abstract] [Full Text] [Related]

  • 39. The efficacy of Bifidobacterium quadruple viable tablet in the treatment of diarrhea predominant irritable bowel syndrome: protocol for a randomized, double-blind, placebo-controlled, multicenter trial.
    Bai T, Zeng H, Long Y, Li X, Sun X, Lan Y, Gao L, Zhang L, Feng Z, Hou X.
    Trials; 2020 Jun 30; 21(1):597. PubMed ID: 32605578
    [Abstract] [Full Text] [Related]

  • 40. Double-Blind Placebo-Controlled Study of Rifaximin and Lactulose Hydrogen Breath Test in Gulf War Veterans with Irritable Bowel Syndrome.
    Tuteja AK, Talley NJ, Stoddard GJ, Verne GN.
    Dig Dis Sci; 2019 Mar 30; 64(3):838-845. PubMed ID: 30370492
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.